Navigation Links
The new born nightmare

Newborns are more likelier to develop a serious intestinal disorder if they are given the commonly prescribed antibiotic erythromycin, say US scientists. A research team from Lousiana University has linked use of this drug to pyloric stenosis, a condition that affects about 1 in 400 newborns and it is the most common cause of abdominal surgery in infants.

Using the Regenstrief Medical Record System – a comprehensive database that stores information on diagnoses, operative reports, pharmacy records and physician observations –the investigators studied 13,576 babies born between January 1995 and December 2000.//

They found that those babies given oral erythromycin during the first two weeks of life were 12 times more likely to develop pyloric stenosis than those who were not, although babies treated with erythromycin eye ointment, which is regularly used to combat conjunctivitis, did not have much risk.

“The link between erythromycin and pyloric stenosis is an important finding which will make a difference to the health of babies,” said Dr Lida Carlman, the lead researcher, adding that the study was only made possible by the vast amount of data stored in the Regenstrief system.

The researchers conclude that erythromycin should be used with great precaution in a baby’s first four weeks of life.
br>
'"/>




Page: 1

Related medicine news :

1. Wake-up Call: Two-thirds of Briton Spend Many Sleeping Moments Awake!
2. A Wake-up Call by MPs to Ensure Timely Care to Stroke Victims
3. Stem cell cure for peripheral vascular disease: New hope on the horizon
4. New device for detecting artery blockages
5. Vitamins suppress artery injury after transplant
6. Cocaine may cause aneurysms for the coronart artery
7. Soy, Omega 3s convalesce artery health
8. Erectile dysfunction: an early warning sign of clinically silent coronary artery disease?
9. Experts urging artery screening in the UK
10. Evidence Links Protein Damage to Neurodegenerative diseases like Parkinsons and Alzheimers
11. Fight Heart disease and Pain with Meditation
Post Your Comments:
*Name:
*Comment:
*Email:


(Date:4/24/2017)... , ... April 24, 2017 , ... Come to PAINWeekEnd ... 4200 Jim Walter Blvd, for an educational and exciting 2-day program. , An ... staff hearing this before they approach patients” about the course entitled Ain't Misbehavin': Decreasing ...
(Date:4/24/2017)... ... April 24, 2017 , ... Donna Parker, L. Ac. reads ... not found any of them to be very practical. She wanted to write a ... make changes in their health. It prompted her in writing “ A Clear Path ...
(Date:4/24/2017)... ... , ... “Reflections of God’s Work”: an enlightening collection of life lessons leading ... of published author, Jerri Broglin, a survivor of great loss who gained insight on ... eye-opener for those searching for answers, as we are finding the answers that are ...
(Date:4/24/2017)... , ... April 24, 2017 , ... “The Saint with ... with Trin, and Omega Station” is the creation of published author, Chris Jackson. ... Metroplex where he works in the Dallas Independent School District teaching English. He is ...
(Date:4/24/2017)... (PRWEB) , ... April 24, 2017 , ... Life of ... University of Florida. The event will be held at 7:30 pm on May 10th ... Block and Drew Copeland of Sister Hazel, will support the UF Collegiate Recovery Community ...
Breaking Medicine News(10 mins):
(Date:4/20/2017)... April 20, 2017 NeuroVive Pharmaceutical AB ... announced positive preclinical results demonstrating anti-fibrotic effects ... non-alcoholic steatohepatitis (NASH), in an additional well-validated ... NV556 has previously shown similar anti-fibrotic effects ... NeuroVive,s scientists present novel data demonstrating anti-fibrotic ...
(Date:4/19/2017)... Calif. , April 19, 2017  IRIDEX Corporation ... will release financial results for the first quarter 2017 ... 2017.  The Company,s management team will host a corresponding ... p.m. ET. Investors interested in listening to ... 707-0665 for domestic callers or (703) 326-3030 for international ...
(Date:4/19/2017)... April 19, 2017  Sorrento Therapeutics, Inc. (NASDAQ: ... biopharmaceutical company developing new treatments for cancer and ... of its previously announced underwritten public offering of ... public offering price of $2.00 per share, before ... expenses payable by Sorrento.  The net proceeds to ...
Breaking Medicine Technology: